InterPAD - DETAILS

Carfilzomib, 868540-17-4, Kyprolis, Carfilzomib (PR-171), PR-171, UNII-72X6E3J5AR, Carfilzomib (PR171), NSC-758252, 72X6E3J5AR, DTXSID4048690, CHEBI:65347, CHEMBL451887, DTXCID0028616, NSC 758252, (alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide, N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide, NCGC00249613-01, (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide, C40H57N5O7, (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide, (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide, (S)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide, L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-, Carfilzomib [USAN], CAS-868540-17-4, Carfilzomib [USAN:INN], carfilzomibum, MFCD11040997, Kyprolis (TN), (2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide, N-((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-L-leucyl-N-((2S)-4-methyl-1-((2R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-L-phenylalaninamide, Carfilzomib; PR171, CARFILZOMIB [MI], CARFILZOMIB [INN], CARFILZOMIB [JAN], CARFILZOMIB [VANDF], SCHEMBL85165, CARFILZOMIB [WHO-DD], MLS006011102, Carfilzomib (JAN/USAN/INN), GTPL7420, AMY4357, CARFILZOMIB [ORANGE BOOK], L01XX45, BLMPQMFVWMYDKT-NZTKNTHTSA-N, EX-A2037, ONO-7057, Tox21_113079, BDBM50277889, NSC756640, NSC758252, s2853, AKOS025401910, Tox21_113079_1, CCG-270405, CS-0984, CS-W004540, DB08889, NSC-756640, NCGC00249613-02, NCGC00249613-03, NCGC00249613-08, NCGC00249613-11, NCGC00249613-13, (S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide, AC-27051, AS-17059, HY-10455, SMR004660024, NS00072616, SW218090-2, D08880, AB01565867_02, SR-01000941582, J-501773, SR-01000941582-1, Q15366934, (Alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe nylalaninamide, L-PHENYLALANINAMIDE, (.ALPHA.S)-.ALPHA.-((4-MORPHOLINYLACETYL)AMINO)BENZENEBUTANOYL-L-LEUCYL-N-((1S)-3-METHYL-1-(((2R)-2-METHYLOXIRANYL)CARBONYL)BUTYL)-, N-((2S)-2-((Morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-L-leucyl-L-phenylalanin-N-((2S)-4-methyl-1-((2R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amide

Name	Carfilzomib
PubChem CID	11556711
Molecular Weight	719.9g/mol
Synonyms	Carfilzomib, 868540-17-4, Kyprolis, Carfilzomib (PR-171), PR-171, UNII-72X6E3J5AR, Carfilzomib (PR171), NSC-758252, 72X6E3J5AR, DTXSID4048690, CHEBI:65347, CHEMBL451887, DTXCID0028616, NSC 758252, (alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide, N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide, NCGC00249613-01, (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide, C40H57N5O7, (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide, (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide, (S)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide, L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-, Carfilzomib [USAN], CAS-868540-17-4, Carfilzomib [USAN:INN], carfilzomibum, MFCD11040997, Kyprolis (TN), (2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide, N-((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-L-leucyl-N-((2S)-4-methyl-1-((2R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-L-phenylalaninamide, Carfilzomib; PR171, CARFILZOMIB [MI], CARFILZOMIB [INN], CARFILZOMIB [JAN], CARFILZOMIB [VANDF], SCHEMBL85165, CARFILZOMIB [WHO-DD], MLS006011102, Carfilzomib (JAN/USAN/INN), GTPL7420, AMY4357, CARFILZOMIB [ORANGE BOOK], L01XX45, BLMPQMFVWMYDKT-NZTKNTHTSA-N, EX-A2037, ONO-7057, Tox21_113079, BDBM50277889, NSC756640, NSC758252, s2853, AKOS025401910, Tox21_113079_1, CCG-270405, CS-0984, CS-W004540, DB08889, NSC-756640, NCGC00249613-02, NCGC00249613-03, NCGC00249613-08, NCGC00249613-11, NCGC00249613-13, (S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide, AC-27051, AS-17059, HY-10455, SMR004660024, NS00072616, SW218090-2, D08880, AB01565867_02, SR-01000941582, J-501773, SR-01000941582-1, Q15366934, (Alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe nylalaninamide, L-PHENYLALANINAMIDE, (.ALPHA.S)-.ALPHA.-((4-MORPHOLINYLACETYL)AMINO)BENZENEBUTANOYL-L-LEUCYL-N-((1S)-3-METHYL-1-(((2R)-2-METHYLOXIRANYL)CARBONYL)BUTYL)-, N-((2S)-2-((Morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-L-leucyl-L-phenylalanin-N-((2S)-4-methyl-1-((2R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amide
Drug Type	Small molecule
Formula	C₄₀H₅₇N₅O₇
SMILES	CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
InChI	1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
InChIKey	BLMPQMFVWMYDKT-NZTKNTHTSA-N
CAS Number	868540-17-4
ChEMBL ID	CHEMBL451887
ChEBI ID	CHEBI:65347
TTD ID	D00UVA
Drug Bank ID	DB08889
KEGG ID	D08880
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Curcumin, Carfilzomib
Partner Name	Curcumin
Disease Info	[ICD-11: 2A83.1]	Plasma cell myeloma		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Down-regulation	Expression	CDH13	hsa1012
	Up-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Phosphorylation	NFKBIA	hsa4792
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	U266B1	Plasma cell myeloma	Homo sapiens (Human)	CVCL_0566
Result	Curcumin significantly ameliorates CFZ cytotoxic effect. Induction of p53/p21 axis and G0/G1 cell cycle arrest were more pronounced for the CFZ-curcumin combination